EUVIMEDEUVIMED entdecken
Crossref

Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database

T. Nagase, K. Shinozaki

Die Pharmazie · 01.12.2025 · 80 (11-12)

DOI: 10.31083/ph.2025.5660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 01.12.2025. Verfasst von T. Nagase und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zolbetuximab, a monoclonal antibody against claudin-18.2 (CLDN18.2), improves outcomes in CLDN18.2-positive gastric cancer, but gastrointestinal adverse events—especially nausea and vomiting—are frequently reported. Using PMDA-JADER (April 2004–March 2025), we identified individual case safety reports (ICSRs) listing zolbetuximab as a suspected drug and defined the outcome with MedDRA-concordant preferred terms (nausea, vomiting, nausea and vomiting, retching). Within zolbetuximab reports, binary logistic regression with sex (male reference) and age (

Zitieren

APA

Nagase, T., & Shinozaki, K. (2025). Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database. Die Pharmazie, 80(11-12). https://doi.org/10.31083/ph.2025.5660

Vancouver

Nagase T, Shinozaki K. Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database. Die Pharmazie. 2025;80(11-12). doi:10.31083/ph.2025.5660

BibTeX
@article{Nagase2025,
  author = {Nagase, T. and Shinozaki, K.},
  title = {Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database},
  journal = {Die Pharmazie},
  year = {2025},
  volume = {80},
  number = {11-12},
  doi = {10.31083/ph.2025.5660}
}
Kostenlos starten →